Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo

Objective The study objective was to characterize subgroups of Asia‐Pacific patients with type 2 diabetes who achieved different glycated hemoglobin (HbA1c) targets on tirzepatide treatment. Methods This was a post hoc analysis of the SURPASS AP‐Combo study. Baseline characteristics, changes in meta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Obesity (Silver Spring, Md.) Md.), 2024-06, Vol.32 (6), p.1102-1113
Hauptverfasser:	Bao, Yuqian, Han, Lin, Du, Liying, Ji, Linong
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antidiabetics Blood Glucose - drug effects Blood Glucose - metabolism Blood pressure Body Mass Index Cardiovascular disease Clinical trials Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Fasting Female Gastric Inhibitory Polypeptide Glucagon-Like Peptide-2 Receptor Glucose Glycated Hemoglobin - analysis Glycated Hemoglobin - metabolism Glycemic Control - methods Hemoglobin Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Insulin Male Metabolism Middle Aged Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective The study objective was to characterize subgroups of Asia‐Pacific patients with type 2 diabetes who achieved different glycated hemoglobin (HbA1c) targets on tirzepatide treatment. Methods This was a post hoc analysis of the SURPASS AP‐Combo study. Baseline characteristics, changes in metabolic markers, and safety were compared between tirzepatide‐treated patients achieving HbA1c
ISSN:	1930-7381 1930-739X 1930-739X
DOI:	10.1002/oby.24030